Versant Ventures related stories
All articles and analysis
Chinook Therapeutics bags $106m in latest financingChinook Therapeutics, a Vancouver, British Columbia-based developer of precision medicines for kidney disease, has raised US$106 million in financing.
Versant Ventures commits $30m to Matterhorn BiosciencesVersant Ventures has launched Matterhorn Biosciences AG, a biotech company focused on developing T cell receptor therapies.
- VC-backed Pandion Therapeutics debuts IPO
Watertown, Massachusetts-based Pandion Therapeutics Inc, a developer of treatments for patients suffering from autoimmune diseases, has raised $135 million for its IPO after pricing its 7.5 million shares at $18 per share.
- VC-backed Repare Therapeutics closes Nasdaq IPO, raises $253m
Repare Therapeutics, a Boston- and Montreal-based precision oncology company, has closed its initial public offering on the NASDAQ.
- VC-backed Repare Therapeutics goes public, raises $220m
Repare Therapeutics, a Boston- and Montreal-based precision oncology company, has raised about US$220 million for its IPO after pricing its 11 million shares at US$20 per share.
- Lycia Therapeutics lands $50m
Biotechnology company Lycia Therapeutics, Inc has secured $50 million in funding.
- VC-backed Ebb Therapeutics recruits Breus as sleep advisor
Pittsburgh-based Ebb Therapeutics, a sleep technology company, has named Dr. Michael Breus as a sleep advisor.
- VC-backed Chinook Therapeutics to merge with Aduro Biotech
Chinook Therapeutics, a Vancouver-based developer of precision medicines for kidney disease, has agreed to merge with Aduro Biotech.
- Monte Rosa Therapeutics scores $32.5m Series A
Boston-based Monte Rosa Therapeutics, a biotechnology company, has raised $32.5 million in Series A funding.
VC-backed Inari Medical debuts IPOInari Medical, a developer of products that treat patients suffering from venous diseases, has raised about $156 million for its IPO after pricing its over 8.2 million shares at about $19 per share.